Response to Sunitinib in Medullary Thyroid Cancer
Overview
Authors
Affiliations
New Treatment Options for Metastatic Thyroid Cancer.
Kunadharaju R, Goyal G, Rudraraju A, Silberstein P Fed Pract. 2019; 32(Suppl 7):21S-26S.
PMID: 30766126 PMC: 6375431.
Management of hereditary medullary thyroid carcinoma.
Pappa T, Alevizaki M Endocrine. 2016; 53(1):7-17.
PMID: 26839093 DOI: 10.1007/s12020-016-0873-1.
Activated RET and ROS: two new driver mutations in lung adenocarcinoma.
Bos M, Gardizi M, Schildhaus H, Buettner R, Wolf J Transl Lung Cancer Res. 2015; 2(2):112-21.
PMID: 25806222 PMC: 4369857. DOI: 10.3978/j.issn.2218-6751.2013.03.08.
Medical management of metastatic medullary thyroid cancer.
Maxwell J, Sherman S, ODorisio T, Howe J Cancer. 2014; 120(21):3287-301.
PMID: 24942936 PMC: 4268545. DOI: 10.1002/cncr.28858.
Advanced medullary thyroid cancer: pathophysiology and management.
Ferreira C, Siqueira D, Ceolin L, Maia A Cancer Manag Res. 2013; 5:57-66.
PMID: 23696715 PMC: 3658436. DOI: 10.2147/CMAR.S33105.